President & CEO

Dr. Yang Shao is a visionary scientist and entrepreneur committed to advancing precision oncology through innovation in cancer genomics. Early in his career, he recognized the transformative potential of next-generation sequencing (NGS) and has since dedicated his work to integrating molecular diagnostics into clinical practice—guided by the belief that “Cancer is a word, not a sentence.”

Dr. Shao holds a B.Sc. in Immunology and a Ph.D. in Cancer Biology from the University of Toronto. In 2012, he founded Geneseeq, which has grown to over 1,000 employees across Canada and China. The company operates CAP-, CLIA-, and ISO 15189-accredited laboratories, serving patients in more than 20 countries, and holds a leading market share in China with over one million tumor samples processed to date. Geneseeq also runs an ISO 13485-certified manufacturing facility producing NGS-based IVD kits approved by regulatory agencies worldwide.

A strong advocate for science-driven innovation, Dr. Shao holds over 50 patents and has authored more than 200 peer-reviewed publications in leading journals including Cell, Nature Genetics, Journal of Clinical Oncology, and Nature Medicine. He is a Distinguished Professor and board member at Nanjing Medical University, an executive member of the CSCO Clinical Research Expert Committee, and a key contributor to China’s national NGS testing guidelines. He frequently speaks at major international conferences such as ASCO, AACR, and CSCO.

Dr. Shao’s contributions have earned wide recognition, including Forbes 30 Under 30 Asia in Healthcare & Science (2017), the Canada China Business Council’s Young Entrepreneur Gold Award (2018), and the “Innovative China Emerging Entrepreneur” distinction (2019).